Labiotech.eu

News and Trends 30 Mar 2016

German Biotech targets China for Lung Cancer Liquid Biopsies

Epigenomics (Germany and US) has closed a deal to develop and commercialize a new blood-based lung cancer diagnostic in China, one of its highest performing markets. There are many biotech efforts to find treatments for cancer, but a separate strategy to lower cancer mortality is to improve diagnosis – so that people can be treated when […]

March 30, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 30 Mar 2016

Dutch Startup gets €7M for New Cancer Immunotherapy Platform

Gadeta has raised €7M in a series A round, which will fuel the clinical development of its novel TCR platform, starting with a leukemia cell therapy trial. Gadeta is a spin-out of immuno-oncology research at the University Medical Center Utrecht (UMC Utrecht). It was founded in 2015 by the researchers and Utrecht Holdings, the technology transfer […]

March 30, 2016 - 2 minutesmins - By Denise Neves Gameiro

gairdner awards biomedical research crispr hiv

News and Trends 29 Mar 2016

The CRISPR ‘Crew’ continues World Tour of Scientific Prize Collection

CRISPR remains in the spotlight as the scientific discovery of the century. A long list of ‘inventors’ have been awarded the Canada Gairdner Awards, which recognise innovative biomedical research. The Gairdner Foundation (Canada) has chosen its 2016 picks for the ‘world’s best and brightest’ research in the biomedical sciences. The lucky winners this year work […]

March 29, 2016 - 4 minutesmins - By Denise Neves Gameiro

News and Trends 29 Mar 2016

Belgian Cell Therapy Biotech Excelling in Trials to Treat Severe Osteoporosis

Bone Therapeutics (Belgium) has released its financial results for 2015, which show a solid cash position and promising results in treating Bone conditions in ongoing clinical trials. This Belgian Biotech is developing cell therapies to treat a bone diseases like osteoporosis with considerable success so far – and 2015 was a year with plenty of important milestones. These […]

March 29, 2016 - 3 minutesmins - By Denise Neves Gameiro

philipp hemme labiotech conference novartis sachs biotech markus goebel

News and Trends 29 Mar 2016

Interviewing the Managing Director of the $750M Venture Fund of Novartis

This is last interview you will see from SACHS in Zurich. I met with Markus Goebel, the managing director of the Novartis Venture Fund. He almost played at home as he is living few dozen of kilometres outside the city in the lovely Swiss countryside. Novartis Venture Fund originates, as its name can tell, from […]

March 29, 2016 - 2 minutesmins - By Philip Hemme

synbiobeta infographic synthetic biology europe industry biotec oxitec investors evolva deinove

News and Trends 28 Mar 2016

Infographic: A Handy Guide to the European Synthetic Biology Startup Scene

The rise of Synthetic biology has radicalised how the biotech industry innovates, develops and invests. Here is an infographic put together by SynBioBeta (the ‘Activity hub for the SynBio industry’). Synbio is now an essential source of research, particularly in the Greentech field. For example, Deinove (France) has signed major partnerships with the US on Synbio […]

March 28, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 25 Mar 2016

Israeli Pharma gets FDA Approval for New Antibody against Severe Asthma

Teva (Israel) can now commercialize their intravenous drug (Cinqair) in the US, which will help adults with severe asthma. Based near Tel Aviv, Teva is the largest producer of generics, but it is also conducting its own biotech research. These include collaborations with Active Biotech (Sweden) for treatment of Huntington’s disease, and Heptares Therapeutics […]

March 25, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 25 Mar 2016

Biotech of the Week: OSE Pharma, the ‘Significant’ Immunotherapy Player from Paris

This week, we head up full speed from Geneva with our eyes aiming towards Paris. Known for its beauty, bohemian lifestyle and, of course the Eiffel Tower, the Louvre and le baguette, Paris is also the home of OSE Pharma, our Biotech of the Week. City: Paris (France) Founded: 2012 Employees: N/A Financial Data: €24.3M total raised (as of […]

March 25, 2016 - 2 minutesmins - By Joachim Eeckhout

News and Trends 24 Mar 2016

Endeavouring to Establish Europe’s Largest MedTech Fund

The VC Endeavour Vision (Switzerland) has finally closed its Endeavour Medtech Growth (EMG) at €250M. This makes it one of the largest funds dedicated to MedTech innovation worldwide! Largely oversubscribed, the fund reached its hard cap and closed well above its €150M target, finally reaching €250M – the largest fund dedicated to medtech in Europe, and one of the largest pure […]

March 24, 2016 - 2 minutesmins - By Dani Bancroft

probiodrug alzheimers mark booth cbo e1458823157506

News and Trends 24 Mar 2016

Leading German Biotech recruits New talent for Fight against Alzheimer’s

Probiodrug (Germany) has hired Mark Booth as Chief Business Officer to propel this Pharma’s global strategy. Among other important roles, Booth was president of Takeda North America. Probiodrug is a Biopharma focused on developing treatments for Alzheimer’s disease. Its strategy is based on the elimination of pyroglutamated Abeta (pGlu), which is one of the way Alzheimer’s […]

March 24, 2016 - 2 minutesmins - By Denise Neves Gameiro

humabs influenza antibody infectious cellclone medimmune

News and Trends 24 Mar 2016

Novel Antibody for Influenza gets FDA Fast-Track Approval

Humabs (Switzerland) has gotten some serious recognition for its antibody platform, as its candidates for Influenza have received FDA fast-track designation. A biologic therapy for Influenza A has been granted Fast Track Designation by the FDA, a ‘programme to accelerate the treatment commercialisation. The therapy is based on an antibody (MEDI8852) that was initially developed by […]

March 24, 2016 - 3 minutesmins - By Denise Neves Gameiro

maat pharma autologous microbiome therapy

News and Trends 23 Mar 2016

French Microbiome Startup Gets €10M to Start Clinical Trials

MaaT Pharma (France) has raised €10M in a series A round, which will allow it to start clinical development of its autologous therapy for imbalance of the Gut Microbiome. MaaT Pharma is developing microbiome-based therapies with an autologous (self-sourced) approach. This means that the patient suffering from dysbiosis is treated with their own microbiome, samples of which were […]

March 23, 2016 - 3 minutesmins - By Denise Neves Gameiro

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

German Biotech targets China for Lung Cancer Liquid Biopsies

Dutch Startup gets €7M for New Cancer Immunotherapy Platform

The CRISPR ‘Crew’ continues World Tour of Scientific Prize Collection

Belgian Cell Therapy Biotech Excelling in Trials to Treat Severe Osteoporosis

Interviewing the Managing Director of the $750M Venture Fund of Novartis

Infographic: A Handy Guide to the European Synthetic Biology Startup Scene

Israeli Pharma gets FDA Approval for New Antibody against Severe Asthma

Biotech of the Week: OSE Pharma, the ‘Significant’ Immunotherapy Player from Paris

Endeavouring to Establish Europe’s Largest MedTech Fund

Leading German Biotech recruits New talent for Fight against Alzheimer’s

Novel Antibody for Influenza gets FDA Fast-Track Approval

French Microbiome Startup Gets €10M to Start Clinical Trials

Subscribe to our newsletter to get the latest biotech news!